IMPEDIMED LIMITED — Director's Dealing 2018

Jun 11, 2018

==> picture [226 x 42] intentionally omitted <==

12 June 2018

ASX ANNOUNCEMENT

Appendix 3Y Change of Director’s Interest Notice

Attached is an Appendix 3Y – Change of Director’s Interest Notice in respect of changes in the relevant interests in securities held by Richard Carreon, Managing Director & CEO.

On 5 June 2018, Mr Carreon acquired 139,367 Ordinary Shares through vesting of Options and between 5 June 2018 and 6 June 2018 sold a total of 105,000 Ordinary Shares. The sale of the shares by Mr Carreon was required to fund the exercise of the options and an immediate US tax liability arising from the exercise of these Options. The Options were granted in 2013 as part of the 2014 financial year Long Term Incentive Plan.

Following this acquisition and sale, Mr Carreon has now increased his holdings to 869,225 Ordinary Shares. In addition, Mr Carreon holds 14,434,460 Options and 1,732,000 Performance Rights, which are subject to various time-based and performance conditions.

Leanne Ralph Company Secretary

Media Contact:

Kyahn Williamson, WE Buchan T: +61 3 9866 4722 E: kwilliamson@buchanwe.com.au

About ImpediMed

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is the world leader in the design and manufacture of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of tissue composition and fluid status.

ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO[®] for multiple indications including heart failure and lymphoedema, sold in select markets globally.

For more information, visit www.impedimed.com.

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity: ImpediMed Limited ABN: 089 705 144

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Richard Carreon
Date of last notice	11 December 2017

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
Date of change	5 June 2018 for conversion of options to shares 5 June and 6 June 2018 for sale of Shares
No. of securities held prior to change	14,573,827 Options 1,732,000 Performance Shares 834,858 Fully Paid Ordinary Shares
Class	1. Options 2. Fully Paid Ordinary Shares
Number acquired	139,367 Fully Paid Ordinary Shares

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Number disposed	139,367 Options 105,000 Fully Paid Ordinary Shares
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil for the conversion of Options to Fully Paid Ordinary Shares $48,821.70 for the disposal of Ordinary Shares
No. of securities held after change	14,434,460 Options 1,732,000 Performance Shares 869,225 Fully Paid Ordinary Shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Conversion of options to Fully Paid Ordinary Shares and on-market trade of disposal of Ordinary Shares.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract Nature of interest Name of registered holder (if issued securities) Date of change No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed Interest acquired Interest disposed Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

Interest after change

Part 3 –[+] Closed period

Part 3 –+Closed period
Were the interests in the securities or contracts detailed above traded during a+closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?
If prior written clearance was provided, on what date was this provided?

Date of Notice: 12 June 2018

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 3